⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JANX News
Janux Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
JANX
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
businesswire.com
JANX
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
businesswire.com
JANX
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
businesswire.com
JANX
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer
businesswire.com
JANX
GILD
AMGN
Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study
businesswire.com
JANX
Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC
businesswire.com
JANX
Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC
businesswire.com
JANX
Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
businesswire.com
JANX